Amniotics AB Invites by European Innovation Council to Finalise Grant Agreement with the as Part of Consortium Set to Receive Grant of EUR 3.8 Million from the EIC Pathfinder Programme

Amniotics AB (publ) announced it has been invited to finalise a grant agreement with the European Innovation Council (EIC) as part of a consortium set to receive a grant of EUR 3.8 Million from the EIC Pathfinder programme. This grant will fund the development of iPS derived, enhanced Natural Killer (NK) cells by a consortium led by Amniotics AB. Other participants are Lund University, Medizinische Hochschule Hannover and the University of Copenhagen.

Following the invitation Amniotics and the partners in the project will finalise the agreement with the EIC over the coming months. After agreement is signed, expect to get the project started in Q1- 2023 and it will continue for thirty-six months.